gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Placental growth factor

PlGF, placental growth factor, placenta growth factor, PIGF
This gene encodes a growth factor found in placenta which is homologous to vascular endothelial growth factor. Alternatively spliced transcripts encoding different isoforms have been found for this gene.[provided by RefSeq, Jun 2011] (from NCBI)
Sponsored links
Top mentioned proteins: vascular endothelial growth factor, FMS, HAD, AGE, CAN
Papers using PlGF antibodies
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kitajewski Jan et al., In Journal of Angiogenesis Research, 2004
... PlGF was obtained from Research Diagnostics Institute ...
Papers on PlGF
Placental growth factor enhances angiogenesis in human intestinal microvascular endothelial cells via PI3K/Akt pathway: potential implications of inflammation bowel disease.
Zhang et al., Shanghai, China. In Biochem Biophys Res Commun, Feb 2016
Placental growth factor (PlGF) is a specific regulator of pathological angiogenesis and is upregulated in the sera of IBD patients.
Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.
Verlohren et al., Oxford, United Kingdom. In N Engl J Med, Feb 2016
BACKGROUND: The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) is elevated in pregnant women before the clinical onset of preeclampsia, but its predictive value in women with suspected preeclampsia is unclear.
Vascular endothelial growth factor pathway in endometriosis: genetic variants and plasma biomarkers.
Fassbender et al., Leuven, Belgium. In Fertil Steril, Feb 2016
OBJECTIVE: To study single nucleotide polymorphisms (SNPs) involved in angiogenesis (VEGF, PLGF, VEGFR1, VEGFR2, HIF-1α) and plasma levels of the corresponding proteins (VEGF, PLGF, sVEGFR1, sVEGFR2) in women with and without endometriosis.
Response to anti-VEGF-A treatment of endothelial cells in vitro.
Nicolò et al., Genova, Italy. In Exp Eye Res, Feb 2016
Cell viability and then expression and secretion of VEGF-A, VEGF-B, VEGF-C and PlGF were evaluated respectively by Real Time-PCR and ELISA.
Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma.
Van Vlierberghe et al., Gent, Belgium. In Bmc Cancer, Dec 2015
We previously showed that the inhibition of placental growth factor (PlGF) exerts antitumour effects and induces vessel normalisation, possibly reducing hypoxia.
Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection.
Zhang et al., Shanghai, China. In Plos One, Dec 2015
PURPOSE: To evaluate changes in the concentrations of placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A) in aqueous humor of patients with neovascular glaucoma (NVG) before and after an intravitreal injection of ranibizumab (IVR) and to determine the underlying correlation between the levels.
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
Gentzler et al., Charlottesville, United States. In Transl Lung Cancer Res, Oct 2015
One of the best characterized group of protein factors for angiogenesis include the members of the vascular endothelial growth factor (VEGF) family, consisting of VEGF-(A-D), and placenta growth factor (PIGF).
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Van Cutsem et al., Barcelona, Spain. In Lancet Oncol, Aug 2015
We also measured the concentration of 15 proteins of interest-angiopoietin 2, interleukin 6, interleukin 8, placental growth factor, soluble TIE-1, soluble VEGFR1, VEGF-A, VEGF-C, VEGF-D, VEGF-A isoform 121, bone morphogenetic protein 7, macrophage colony-stimulating factor, stromal cell-derived factor-1, tissue inhibitor of metalloproteinase 2, and von Willebrand factor-in plasma samples from 611 patients.
Kozlova et al., In Ross Fiziol Zh Im I M Sechenova, Aug 2015
The important aspects of the interaction of T cells and EGF, TGF-P, FGF, VEGF, PlGF, HGF/SF in normal and pathological conditions are shown in this review.
VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature.
Săftoiu et al., In Rom J Intern Med, Jul 2015
VEGF protein family currently comprises several members: VEGF (or VEGF-A), VEGF-B, VEGF-C and VEGF-D, VEGF-F, placental growth factor (PlGF), and their receptors VEGFR-1, VEGFR-2 and VEGFR-3.
A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain.
Kuner et al., Heidelberg, Germany. In Cancer Cell, Jul 2015
Tumor-derived VEGF-A, PLGF-2, and VEGF-B augment pain sensitivity through selective activation of VEGF receptor 1 (VEGFR1) expressed in sensory neurons in human cancer and mouse models.
First trimester serum tests for Down's syndrome screening.
Alfirevic et al., Liverpool, United Kingdom. In Cochrane Database Syst Rev, 2014
We evaluated 78 test combinations formed from combinations of 18 different tests, with or without maternal age; ADAM12 (a disintegrin and metalloprotease), AFP (alpha-fetoprotein), inhibin, PAPP-A (pregnancy-associated plasma protein A, ITA (invasive trophoblast antigen), free βhCG (beta human chorionic gonadotrophin), PlGF (placental growth factor), SP1 (Schwangerschafts protein 1), total hCG, progesterone, uE3 (unconjugated oestriol), GHBP (growth hormone binding protein), PGH (placental growth hormone), hyperglycosylated hCG, ProMBP (proform of eosinophil major basic protein), hPL (human placental lactogen), (free αhCG, and free ßhCG to AFP ratio.
Use of biochemical tests of placental function for improving pregnancy outcome.
Thornton et al., Manchester, United Kingdom. In Cochrane Database Syst Rev, 2014
There are many other placental products that could be employed as surrogates of placental function, including: placental growth factor (PlGF), human chorionic gonadotrophin (hCG), plasma protein A (PAPP-A), placental protein 13 (PP-13), pregnancy-specific glycoproteins and progesterone metabolites and further studies should be encouraged to investigate these other placental products.
Hypertension: an immune disorder?
Tracey, United States. In Immunity, 2014
(2014) implicate PlGF signaling in a reservoir of splenic T cells.
The angiogenic factor PlGF mediates a neuroimmune interaction in the spleen to allow the onset of hypertension.
Lembo et al., Italy. In Immunity, 2014
Here we showed a splenic role for placental growth factor (PlGF), which accounts for the onset of hypertension, through immune system modulation.
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Morrow et al., Boston, United States. In J Thromb Thrombolysis, 2012
Higher concentration of PlGF after ACS is associated with long-term risk of recurrent cardiovascular events independent of traditional risk factors.
CD105 and placental growth factor--potent prognostic factors in childhood acute lymphoblastic leukaemia.
Nowicki et al., Poznań, Poland. In Leuk Res, 2012
CD105 and placental growth factor--potent prognostic factors in childhood acute lymphoblastic leukaemia.
Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?
Gandley et al., Pittsburgh, United States. In Hypertension, 2012
Data suggest that identifying women with consistently low plasma placental growth factor (PGF) during pregnancy may provide a greater understanding of preeclampsia pathophysiology and may provide more focused research and clinical activities.
Maternal serum placental growth factor in second trimester trisomy 21 pregnancies.
Spencer et al., United Kingdom. In Prenat Diagn, 2012
Although we have found no significant change in the second trimester levels of PlGF in trisomy 21 pregnancies, there remains wide disagreement within the literature on the behaviour of this marker during pregnancies of this syndrome.
The trend of VEGF-A and PlGF in pregnant patients: a perspective case-control study on 214 women.
Nardelli et al., Padova, Italy. In Clin Exp Obstet Gynecol, 2011
statistically significant decrease compared to physiological gestation in spontaneous and threatened abortions (p < 0.0001) and in ectopic pregnancies (p < 0.0001), and threatened premature delivery and uterine hypercontractility (p < 0.01)
share on facebooktweetadd +1mail to friends